Oncology / Other
Disease Group
Oncology / Other
Disease Group Profile
As ACRRU continues to grow, we expect to expand our research to every major disease group. In this section, we feature studies in several of our nascent disease group areas, including Melanoma and Brain.
Disease Group Clinical Trials
CAM20CV
RECOVER: Phase 2 Randomized, Double-Blind Trial Treating Hospitalized Patients with COVID-19 with Camostat Mesilate, a TMPRSS2 Inhibitor
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER) »
ACCRU-ITOG-1504
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Resistant Differentiated Thyroid Cancers: A Phase II Study
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) »
CE.6
Neuro Oncology – A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
MORAb-004-203-STS
Sarcoma – A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation (SOURCE) »
RU241210I
Thyroid/Endocrine – Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer »
RU241306I
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Meta static Thyroid Cancers
RU261206I
Melanoma – Randomized Phase II Study of AB (nab-paclitaxel Abraxane, Bevacizumab) versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma